Syrup composition containing phage associated lytic enzymes
View Patent ↗The present invention discloses a method and composition for the treatment of bacterial infections by the parenteral introduction of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for that bacteria and an appropriate carrier for delivering the lytic enzyme into a patient. The injection can be done intramuscularly, subcutaneously, or intravenously.
1. A parenteral therapeutic agent for the treatment of bacterial infections comprising:
a) an effective amount of at least one enzyme genetically coded for by at least one specific bacteriophage specific for a specific bacteria, wherein said at least one enzyme is selected fro the group consisting of at least one unaltered lytic enzyme, at least one shuffled lytic enzyme, at least one chimeric lytic enzyme at least one holin protein, and combinations thereof, said at least one enzyme having the ability to digest a cell wall of a specific said bacteria;
b) a parenteral carrier for the parenteral delivery of said at least one lytic enzyme to the site of the infection, said parenteral carrier comprising:
i) a fluid selected from the group consisting of distilled water, a saline solution, albumin, a serum, and any combinations thereof;
ii) supplemental additive selected from the group consisting of saline, buffer, and combinations thereof; and
iii) nutritional agents selected from the group consisting of dextrose, mannitol, sorbitol, lactose, gelatin, and combinations thereof.
2. The parenteral therapeutic agent according to claim 1 , comprising a vasoconstriction agent.
3. The parenteral therapeutic agent according to claim 1 , wherein the at least one said enzyme is for the treatment of Pseudomonas.
4. The parenteral therapeutic agent according to claim 1 , wherein the at least one said enzyme is for the treatment of Streptococcus.
5. The parenteral therapeutic agent according to claim 1 , wherein the at least one said enzyme is for the treatment of Staphylococcus.
6. The parenteral therapeutic agent according to claim 1 , wherein the at least one said enzyme is for the treatment of Clostridium.
7. The parenteral therapeutic agent according to claim 1 , wherein said agent further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
8. The parenteral therapeutic agent according to claim 7 , wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.
9. The parenteral therapeutic agent according to claim 1 , wherein said buffer comprises a reducing reagent.
10. The parenteral therapeutic agent according to claim 9 , wherein said reducing reagent is dithiothreitol.
11. The parenteral therapeutic agent according to claim 1 , wherein said buffer comprises a metal chelating reagent.
12. The parenteral therapeutic agent according to claim 11 , wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
13. The parenteral therapeutic agent according to claim 1 , wherein said buffer is a citrate-phosphate buffer.
14. The parenteral therapeutic agent according to claim 1 , further comprising a bactericidal or bacteriostatic agent as a preservative.
15. The parenteral therapeutic agent according to claim 1 , further comprising a concentration of about 100 to about 500,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
16. The parenteral therapeutic agent according to claim 1 , wherein said therapeutic agent is an intravenous therapeutic agent.
17. The parenteral therapeutic agent according to claim 1 , wherein said therapeutic agent is an intramuscular therapeutic agent.
18. The therapeutic agent according to claim 1 , wherein said therapeutic agent is a subcutaneous therapeutic agent.
19. The composition according to any one of claims 1 – 18 , further comprising a parenteral dispenser containing said parenteral therapeutic agent.